Preventive and Therapeutic Effect of Metformin in Head and Neck Cancer: A Concise Review-Reference-Cited by-同舟云学术

Preventive and Therapeutic Effect of Metformin in Head and Neck Cancer: A Concise Review

Published:2023-09-25 Issue:19 Volume:12 Page:6195
ISSN:2077-0383
Container-title:Journal of Clinical Medicine
language:en
Short-container-title:JCM

Author:

Bouland Cyril¹^ORCID,Vanden Eynden Xavier¹,Lalmand Martin¹,Buset Thibaut¹,Yanni Antoine¹,Javadian Rokneddine¹,Rodriguez Alexandra²,Loeb Isabelle¹,Lechien Jérôme R.²³^ORCID,Journe Fabrice³⁴^ORCID,Saussez Sven²³^ORCID,Dequanter Didier¹^ORCID

Affiliation:

1. Department of Stomatology—Maxillofacial Surgery, CHU-Saint-Pierre, Université Libre de Bruxelles (ULB), 1000 Brussels, Belgium

2. Department of Otorhinolaryngology—Head and Neck Surgery, CHU-Saint-Pierre, Université Libre de Bruxelles (ULB), 1000 Brussels, Belgium

3. Laboratory of Human Anatomy and Experimental Oncology, Faculty of Medicine and Pharmacy, Research Institute for Health Sciences and Technology, University of Mons (UMONS), 7000 Mons, Belgium

4. Laboratory of Oncology and Experimental Surgery, Jules Bordet Institute, Université Libre de Bruxelles (ULB), 1070 Brussels, Belgium

Abstract

Background: Head and neck cancer (HNC) is a complex affection. Nowadays, conventional treatments are associated with many side effects, reducing the patient’s quality of life. Recent studies suggest that metformin, a first-line treatment for diabetes, could decrease cancer incidence and improve cancer-related survival rates. Methods: This systematic review summarizes important data from studies evaluating metformin’s contribution to preventing and treating HNC. Results: The results suggest a protective effect of metformin in HNC. However, no consensus has been found on its therapeutic effects. Metformin seems to confer an improved cancer-related survival rate in a diabetic population, but compared to a non-diabetic population, the review could not identify any advantages. Nevertheless, no studies presented a negative impact. Conclusion: In conclusion, the results of this systematic review suggest that HNC patients may benefit from metformin. Indeed, it would reduce the HNC incidence. However, more studies are required to evaluate the effect on cancer-related survival rates.

Publisher

MDPI AG

Subject

General Medicine

Link

https://www.mdpi.com/2077-0383/12/19/6195/pdf

Reference36 articles.

1. Cancer statistics, 2010;Jemal;CA Cancer J. Clin.,2010

2. Effects of metformin on head and neck cancer: A systematic review;Pavan;Oral Oncol.,2015

3. Effect of metformin on the incidence of head and neck cancer in diabetics;Yen;Head Neck,2015

4. Metformin exposure and survival in head and neck cancer: A large population-based cohort study;Alcusky;J. Clin. Pharm. Ther.,2019

5. Lechien, J.R., Seminerio, I., Descamps, G., Mat, Q., Mouawad, F., Hans, S., Julieron, M., Dequanter, D., Vanderhaegen, T., and Journe, F. (2019). Impact of HPV Infection on the Immune System in Oropharyngeal and Non-Oropharyngeal Squamous Cell Carcinoma: A Systematic Review. Cells, 8.